1. Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion

3. Addressing Issues With Endocrine Treatment in Metastatic Disease

4. Patient Cases

5. Patient Case 1

6. Patient Case 1 (cont)

7. What Is the Preferred Treatment Option for This Patient?

8. Is This Patient a Candidate for Chemotherapy?

9. Treatment Selection for Case Patient: Rationale

10. BOLERO-2 Trial: PFS by Central Assessment

11. PALOMA-3: PFS in Intent-To-Treat Population

12. Tolerability Profiles to Consider With Combination Approaches

13. Other Considerations With CDK4/6 Inhibitors

14. Managing Neutropenia Associated With CDK4/6 Inhibitors

15. Guideline Recommendations for ER-Positive/HER2-Negative MBC

16. Patient Case 2

17. Patient Case 2 (cont)

18. QTc Monitoring and CDK4/6 Inhibitors

19. What Is the Preferred Treatment Option for This Patient?

20. Patient Case: Rationale for Treatment Choices

21. The Choice to Use ET Monotherapy or ET in Combination With Another Agent

22. Patient Considerations

23. Drug Interactions With CDK4/6 Inhibitors

24. Concluding Remarks

25. Concluding Remarks (cont)